CA2109796C - Modulation of cellular response to external stimuli - Google Patents

Modulation of cellular response to external stimuli Download PDF

Info

Publication number
CA2109796C
CA2109796C CA002109796A CA2109796A CA2109796C CA 2109796 C CA2109796 C CA 2109796C CA 002109796 A CA002109796 A CA 002109796A CA 2109796 A CA2109796 A CA 2109796A CA 2109796 C CA2109796 C CA 2109796C
Authority
CA
Canada
Prior art keywords
omega
dag
cells
levels
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002109796A
Other languages
English (en)
French (fr)
Other versions
CA2109796A1 (en
Inventor
James A. Bianco
Stuart L. Bursten
Jack W. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CA2109796A1 publication Critical patent/CA2109796A1/en
Application granted granted Critical
Publication of CA2109796C publication Critical patent/CA2109796C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002109796A 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli Expired - Lifetime CA2109796C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US732,227 1985-05-08
US70499291A 1991-05-24 1991-05-24
US704,992 1991-05-24
US73222791A 1991-07-16 1991-07-16
PCT/US1992/004349 WO1992021344A2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
CA2109796A1 CA2109796A1 (en) 1992-12-10
CA2109796C true CA2109796C (en) 2004-04-27

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109796A Expired - Lifetime CA2109796C (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP1214938A3 (OSRAM)
JP (1) JP3566719B2 (OSRAM)
AU (1) AU664189B2 (OSRAM)
CA (1) CA2109796C (OSRAM)
IE (1) IE921683A1 (OSRAM)
IL (1) IL101982A (OSRAM)
WO (1) WO1992021344A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
ATE230990T1 (de) * 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
EP0708645A1 (en) * 1994-03-08 1996-05-01 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
ATE220549T1 (de) * 1994-12-29 2002-08-15 Univ California Verbindungen zur hemmung der ceramid vermittelten signalübertragung
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
CA2335595A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
WO2009096616A1 (en) * 2008-01-31 2009-08-06 Korea Institute Of Science And Technology Composition for inhibiting the activity of inositol 1,4,5-triphosphate receptor subtype iii
WO2009096615A1 (en) * 2008-01-31 2009-08-06 Korea Institute Of Science And Technology Composition for preventing or treating brain cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
IL100533A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.

Also Published As

Publication number Publication date
EP0573617A1 (en) 1993-12-15
EP1214938A3 (en) 2003-08-06
AU2247592A (en) 1993-01-08
JPH07500085A (ja) 1995-01-05
JP3566719B2 (ja) 2004-09-15
CA2109796A1 (en) 1992-12-10
IL101982A (en) 2000-02-29
IL101982A0 (en) 1992-12-30
WO1992021344A3 (en) 1993-12-09
AU664189B2 (en) 1995-11-09
EP1214938A2 (en) 2002-06-19
WO1992021344A2 (en) 1992-12-10
IE921683A1 (en) 1992-12-02
EP0573617A4 (OSRAM) 1994-02-09

Similar Documents

Publication Publication Date Title
US5856115A (en) Assay for identification therapeutic agents
CA2109796C (en) Modulation of cellular response to external stimuli
Cho-Chung Site-Selective 8-Chloro-Cyclic Adenosine 3', 5'-Monophosphate as
EP1778224B1 (en) Flt3 inhibitors for immune suppression
US5440041A (en) Acetal or ketal substituted xanthine compounds
US5340813A (en) Substituted aminoalkyl xanthine compounds
JP2753395B2 (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
US20210145914A1 (en) Plant Extract and Its Therapeutic Use
Liu et al. Inhibitory effect of baicalein on IL‐6‐mediated signaling cascades in human myeloma cells
JP4167733B2 (ja) ＮＦ−κＢ活性化抑制剤
EP3043809B1 (en) Filipendula vulgaris extract and uses thereof
AU2015352042B2 (en) Titled extracts of Cynara scolymus for use in the treatment of mesothelioma
US5795897A (en) Oxohexyl methylxanthine compounds
US9782387B2 (en) Compositions and methods for treating hematological malignancies
Asano et al. Inhibition of murine chronic graft-versus-host disease by the chloroform extract of Tripterygium wilfordii Hook f
JPWO1998055493A1 (ja) 天然型抗腫瘍性又は抗ウイルス性物質およびその用途
AU2014272656A1 (en) Extract of Cynara ssp. and uses thereof
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
Zhu et al. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
HK40120251A (en) Nkt cell ligand-containing liposome composition
JP2024132695A (ja) カチオン選択性イオノフォアを用いてγｃサイトカインのシグナル伝達を阻害する方法
US6472385B1 (en) Compositions and methods to enhance cancer chemotherapy in p53 defective tumors
Perez et al. Inhibition by the anti-mitotic drug doxorubicin of platelet-activating-factor-induced late eosinophil accumulation in rats
KR20050041163A (ko) 토토마이세틴을 포함하는 항종양제

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202